Review





Similar Products

human shh subgroup daoy cell line  (ATCC)
97
ATCC human shh subgroup daoy cell line
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Human Shh Subgroup Daoy Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human shh subgroup daoy cell line/product/ATCC
Average 97 stars, based on 1 article reviews
human shh subgroup daoy cell line - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
ventralization  (Miltenyi Biotec)
94
Miltenyi Biotec ventralization
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Ventralization, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ventralization/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
ventralization - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
shh c24ii  (Miltenyi Biotec)
94
Miltenyi Biotec shh c24ii
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Shh C24ii, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shh c24ii/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
shh c24ii - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
10372 h08h1 beijing  (Sino Biological)
94
Sino Biological 10372 h08h1 beijing
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
10372 H08h1 Beijing, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/10372 h08h1 beijing/product/Sino Biological
Average 94 stars, based on 1 article reviews
10372 h08h1 beijing - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
recombinant human sonic hedgehog shh protein  (Sino Biological)
94
Sino Biological recombinant human sonic hedgehog shh protein
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Recombinant Human Sonic Hedgehog Shh Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human sonic hedgehog shh protein/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human sonic hedgehog shh protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
full length human shh cdna  (Genecopoeia)
94
Genecopoeia full length human shh cdna
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Full Length Human Shh Cdna, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full length human shh cdna/product/Genecopoeia
Average 94 stars, based on 1 article reviews
full length human shh cdna - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
shh  (Miltenyi Biotec)
94
Miltenyi Biotec shh
MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or <t>DAOY</t> tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.
Shh, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shh/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
shh - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
morphogen concentration  (Miltenyi Biotec)
94
Miltenyi Biotec morphogen concentration
a ) Photographs of the sample holding chamber with four separated sub-chambers each containing four microwells, for growing and imaging organoids with sixteen different organoids arranged one per microwell n = 16 organoids. b ) Schematic overview of tiled image acquisition and example images showing two timepoints, before and after tiled acquisition and image fusion. Scale Bar is 100 micrometers. Time is in hours. n = 16 organoids. c ) Cross section images (day 7) from 16 simultaneously imaged organoids, generated with cells lines labeled with nuclear membrane (lamin, RFP, magenta), plasma membrane (CAAX, RFP, magenta), actin (GFP, green), tubulin (RFP, magenta), and nuclei (histone, GFP, green) and unlabeled WTC-11. d ) Images showing cross section (z-plane) and orthogonal views (y-plane, x-plane) of one organoid from a timecourse lightsheet imaging experiment shown in c. Scale Bar is 100 micrometers. Time is in hours. e ) Maximum intensity projections from a 2-week imaging acquisition of a mosaic organoid (histone, GFP, green; CAAX, RFP, magenta), unlabeled WTC-11). Scale Bar is 500 micrometers. Time is in hours. n = 16 organoids. f ) Images from a 3-week continuous imaging experiment using a NKX2-1:GFP reporter line. The organoids were given SHH <t>morphogen</t> treatment to induce ventral telencephalic patterning of the organoids. Images are false-colored with the green-fire-blue LUT. Scale Bar is 100 micrometers. Time is in hours. n = 4 organoids.
Morphogen Concentration, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/morphogen concentration/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
morphogen concentration - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or DAOY tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.

Journal: bioRxiv

Article Title: Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma

doi: 10.1101/2025.11.20.689490

Figure Lengend Snippet: MEK inhibitor and regorafenib combination has synergistic anti-tumor efficacy in vivo with G3 cell line model A, Schematic of experimental design for drug administration and imaging in CD-1 nude mice implanted intracranially with D341, PDX5950, or DAOY tumor cells (created with BioRender.com ). Mice were randomized to receive vehicle (p.o.), mirdametinib (5 mg/kg or 0.5 mg/kg, p.o.), regorafenib (10 mg/kg, p.o.), or the combination, starting one week post-implantation and continuing three times per week for six weeks. IVIS or MRI imaging was performed weekly starting one week after surgery. B, Representative in vivo bioluminescent images of mice bearing orthotopic D341 tumors from weeks 1 to 5 post-implantation. C, Quantification of bioluminescence signal (BLI) at week 2 post-treatment in the D341 model, showing significant tumor growth reduction in the combination group. Data are presented as mean ± SEM. D, Kaplan–Meier survival curves for mice implanted with D341 cells and treated as described in (B). Group sizes (n) are indicated in the risk table; log-rank test results: *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. E, Left: Representative IHC staining for cleaved caspase-3 in D341 tumors. Right: Quantification of cleaved caspase-3-positive cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. See also Supplementary Figures S5 and S6.

Article Snippet: Human SHH subgroup DAOY cell line was purchased from American Tissue Culture Collection (ATCC, HTB-186).

Techniques: In Vivo, Imaging, Immunohistochemistry

a ) Photographs of the sample holding chamber with four separated sub-chambers each containing four microwells, for growing and imaging organoids with sixteen different organoids arranged one per microwell n = 16 organoids. b ) Schematic overview of tiled image acquisition and example images showing two timepoints, before and after tiled acquisition and image fusion. Scale Bar is 100 micrometers. Time is in hours. n = 16 organoids. c ) Cross section images (day 7) from 16 simultaneously imaged organoids, generated with cells lines labeled with nuclear membrane (lamin, RFP, magenta), plasma membrane (CAAX, RFP, magenta), actin (GFP, green), tubulin (RFP, magenta), and nuclei (histone, GFP, green) and unlabeled WTC-11. d ) Images showing cross section (z-plane) and orthogonal views (y-plane, x-plane) of one organoid from a timecourse lightsheet imaging experiment shown in c. Scale Bar is 100 micrometers. Time is in hours. e ) Maximum intensity projections from a 2-week imaging acquisition of a mosaic organoid (histone, GFP, green; CAAX, RFP, magenta), unlabeled WTC-11). Scale Bar is 500 micrometers. Time is in hours. n = 16 organoids. f ) Images from a 3-week continuous imaging experiment using a NKX2-1:GFP reporter line. The organoids were given SHH morphogen treatment to induce ventral telencephalic patterning of the organoids. Images are false-colored with the green-fire-blue LUT. Scale Bar is 100 micrometers. Time is in hours. n = 4 organoids.

Journal: Nature

Article Title: Morphodynamics of human early brain organoid development

doi: 10.1038/s41586-025-09151-3

Figure Lengend Snippet: a ) Photographs of the sample holding chamber with four separated sub-chambers each containing four microwells, for growing and imaging organoids with sixteen different organoids arranged one per microwell n = 16 organoids. b ) Schematic overview of tiled image acquisition and example images showing two timepoints, before and after tiled acquisition and image fusion. Scale Bar is 100 micrometers. Time is in hours. n = 16 organoids. c ) Cross section images (day 7) from 16 simultaneously imaged organoids, generated with cells lines labeled with nuclear membrane (lamin, RFP, magenta), plasma membrane (CAAX, RFP, magenta), actin (GFP, green), tubulin (RFP, magenta), and nuclei (histone, GFP, green) and unlabeled WTC-11. d ) Images showing cross section (z-plane) and orthogonal views (y-plane, x-plane) of one organoid from a timecourse lightsheet imaging experiment shown in c. Scale Bar is 100 micrometers. Time is in hours. e ) Maximum intensity projections from a 2-week imaging acquisition of a mosaic organoid (histone, GFP, green; CAAX, RFP, magenta), unlabeled WTC-11). Scale Bar is 500 micrometers. Time is in hours. n = 16 organoids. f ) Images from a 3-week continuous imaging experiment using a NKX2-1:GFP reporter line. The organoids were given SHH morphogen treatment to induce ventral telencephalic patterning of the organoids. Images are false-colored with the green-fire-blue LUT. Scale Bar is 100 micrometers. Time is in hours. n = 4 organoids.

Article Snippet: The organoids were treated with the average morphogen concentration of SHH (140 ng/ml, Miltenyi, 130-095-727) from day 3–14 together with purmorphamine (0.21 μM, Miltenyi, 130-104-465).

Techniques: Imaging, Generated, Labeling, Membrane, Clinical Proteomics